Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5428 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
filingDate |
1992-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
1995-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7173578ed808f881ed441f40d0e65225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d919d6b7ce1d8e64c42d078dbd67e68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34d0c48822a7b72bf712c9483324b785 |
publicationDate |
1995-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0567586-B1 |
titleOfInvention |
Use of interleukin-10 in adoptive immunotherapy of cancer |
abstract |
A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor-cell cytoxicity of the TILs and to reduce side-effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient. |
priorityDate |
1991-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |